Press Releases
Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) will host a webcast on June 11 to discuss data from the first two pivotal Phase III studies of baricitinib in rheumatoid arthritis. Data...
Press Releases
Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities
Eli Lilly and Company (NYSE: LLY) announced today the pricing terms of its previously announced cash tender offer for up to $1.6 billion aggregate principal amount of certain of its outstanding debt securities. Holders of notes...
Press Releases
U.S. Food and Drug Administration Approves Humalog® 200 units/mL KwikPen®
The U.S. FDA has approved Humalog® 200 units/mL KwikPen, a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin. Humalog® (insulin lispro 100 units/mL) to improve glycemic control in people with type 1 and type...
Press Releases
Bristol-Myers Squibb Announces the Expiration of its Cash Tender Offer
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced the expiration, as of 11:59 p.m., New York City time, on May 26, 2015, of its previously announced cash tender offer for up to $500 million aggregate principal amount of certain of...
Press Releases
Lilly Sends Employees to Serve in Vulnerable Communities around the World
First Connecting Hearts Abroad volunteers leave this month to help people in need in Thailand, Peru and Tanzania; more teams deploy later this year Marcio Donatelli, a senior marketing associate with the animal health division of...
Press Releases
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Nivolumab (Opdivo, Nivolumab BMS) for the Treatment of Advanced Squamous Non-Small Cell Lung...
Nivolumab is the first PD-1 immune checkpoint inhibitor to receive a positive opinion from the CHMP in advanced non-small cell lung cancer. Opinion based on overall survival benefit demonstrated in CheckMate -017. CHMP positive opinion marks...
Press Releases
Bristol-Myers Squibb Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen
Breakthrough Designation for daclatasvir and sofosbuvir combination is supported by the recently presented ALLY-1 trial in patients with advanced cirrhosis or recurrent hepatitis C (HCV) after liver transplant. FDA Designation signifies that high unmet need still...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read